Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 55,79€ (+1.323,21%). La mediana es de 35,61€ (+808,42%).
| Comprar |
5 |
| Mantener |
13 |
| Vender |
2 |
Noticias Ir al feed de noticias
Tilray Brands to buy HelloMD and build vertically integrated medical cannabis platform in Canada
Tilray Brands announced on June 29 that it will acquire HelloMD's Canadian medical cannabis assets after winning a court-approved sale process. The deal pairs HelloMD's digital telehealth and patient engagement platform with Tilray's cultivation, clinical expertise and national fulfillment to create a connected pathway for patients and practitioners. Tilray highlighted opportunities to expand into adjacent wellness categories like sleep and pain support; financial terms were not disclosed. Shares of Tilray are down more than 50% year-to-date. » Más en finance.yahoo.com
Datos financieros de la empresa
| (EUR) | may 2026 | |
|---|---|---|
| Ingresos | 241,83M | 10,93% |
| Beneficio bruto | 72,39M | 11,49% |
| Beneficio neto | −42,55M | 97,24% |
| EBITDA | 12,75M | 100,78% |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 452,95M€ |
Número de acciones | 111,83M |
Máximo/mínimo de 52 semanas | 19,91€ - 3,15€ |
| Dividendos | No |
Beta | 1,91 |
Ratio P/E | −3,54 |
Ratio PEG | −0,02 |
Ratio P/B | 0,33 |
Ratio P/S | 0,46 |
Perfil de la empresa
| Nombre | TILRAY BRANDS NEW O.N. |
| CEO | Irwin David Simon |
| Sede | Leamington,
on Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Biotecnología |
| Empleados | 3.595 |
Deep Dive
Descubrir activos
Los accionistas de TILRAY BRANDS NEW O.N. también invierten en los siguientes activos
